粪便微生物群组成与转移性乳腺癌CDK4/6抑制剂治疗反应相关:一项前瞻性横断面探索性研究
该前瞻性横断面探索性研究纳入14例接受CDK4/6抑制剂联合内分泌治疗的激素受体阳性/HER2阴性转移性乳腺癌患者,按无进展生存期分为应答者(R)和无应答者(NR)。基线粪便16S测序显示α/β多样性无显著差异,机器学习识别出4个判别物种,随机森林模型AUC为0.946。作者认为结果提供初步线索,若在更大试验中验证,或可假设微生物群调控策略改善CDK4/6抑制剂反应。
要点
- 14例HR+/HER2-转移性乳腺癌患者接受CDK4/6抑制剂联合内分泌治疗,按PFS分为应答者与无应答者。
- α/β多样性在应答者与无应答者间无显著差异,机器学习识别4个判别物种,随机森林AUC为0.946。
- 作者认为结果提供初步线索,若在更大试验中验证,或可假设微生物群调控策略改善CDK4/6抑制剂反应。
核心结论
- 结果提供粪便微生物群参与转移性乳腺癌对CDK4/6抑制剂联合内分泌治疗敏感和/或耐药的初步线索。
- 若在更大试验中验证,或可假设多种微生物群调控策略改善CDK4/6抑制剂反应。
研究设计与样本
- 前瞻性横断面探索性研究,纳入14例接受CDK4/6抑制剂联合内分泌治疗的HR+/HER2-转移性乳腺癌患者。
- 按无进展生存期将患者分为应答者(R)和无应答者(NR)。
- 基线采集粪便样本,采用V3-V4 16S靶向测序评估细菌组成,并研究其与R和NR的统计学关联。
主要发现
- 在门和种水平,R与NR之间α/β多样性无显著差异。
- 机器学习算法识别出4个判别物种:R相关为Bifidobacterium longum和Ruminococcus callidus,NR相关为Clostridium innocuum和Schaalia odontolytica;随机森林建模后AUC为0.946。
- 网络分析显示两个主要细菌物种簇,命名为物种互作组(SIG)1-2,SIG1包含75%的NR相关细菌物种,SIG2包含76%的R相关物种(p < 0.001)。
- 患者循环免疫细胞或生物标志物与细菌物种相对丰度的交叉相关显示具有潜在预后意义的关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cyclin-dependent kinase (CDK)4/6-inhibitors with endocrine therapy represent the standard of treatment of hormone receptor-positive(HR+)/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Gut microbiota seems to predict treatment response in several tumour types, being directly implied in chemotherapy resistance and development of adverse effects. No evidence is available on gut microbiota impact on efficacy of HR+ breast cancer treatment. PATIENTS AND METHODS: We assessed the potential association among faecal microbiota and therapeutic efficacy of CDK4/6-inhibitors on 14 MBC patients classified as responders (R) and non-responders (NR) according to progression-free survival. A stool sample was collected at baseline and V3-V4 16S targeted sequencing was employed to assess its bacterial composition. Statistical associations with R and NR were studied. RESULTS: No significant differences were observed between R and NR in terms of α-/β-diversity at the phylum and species level. Machine-learning (ML) algorithms evidenced four bacterial species as a discriminant for R (Bifidobacterium longum, Ruminococcus callidus) and NR (Clostridium innocuum, Schaalia odontolytica), and an area under curve (AUC) of 0.946 after Random Forest modelling. Network analysis evidenced two major clusters of bacterial species, named Species Interacting Groups (SIG)1-2, with SIG1 harbouring 75% of NR-related bacterial species, and SIG2 regrouping 76% of R-related species (p < 0.001). Cross-correlations among several patients' circulating immune cells or biomarkers and bacterial species' relative abundances showed associations with potential prognostic implications. CONCLUSIONS: Our results provide initial insights into the gut microbiota involvement in sensitivity and/or resistance to CDK4/6-inhibitors + endocrine therapy in MBC. If confirmed in larger trials, several microbiota manipulation strategies might be hypothesised to improve response to CDK4/6-inhibitors.
引用
- Schettini F, Fontana A, Gattazzo F, et al. Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory study. Eur J Cancer. 2023. PMID: 37454444. doi:10.1016/j.ejca.2023.112948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。